Dynavax Technologies | DVAX - Ebit


Dynavax Technologies reported $21.27M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
AbbVie USD 1.45B 4.26B Sep/2025
Adma Biologics USD 49.19M 7.26M Sep/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD -1.5B 5.01B Sep/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 4.04B 1.78B Sep/2025
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
Glaxosmithkline GBP 3.76B 1.69B Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD -9.19B 13.87B Jun/2025
Pfizer USD 4.65B 71M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
TG Therapeutics USD 29.36M 5.48M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025